ARA290 (cibinetide) treatment confers neuroprotective effects in diabetic retinopathy, through modulation of inflammatory mediators.
Paul Canning(University of Ulster), Alan W. Stitt(Queen's University Belfast), Anthony Cerami(Araim Pharmaceuticals (United States)), Michael Brines(Northwell Health), Lynsey-Dawn Allen(Queen's University Belfast), Olivia O'Leary(Queen's University Belfast)
Investigative Ophthalmology & Visual Science
July 22, 2019
Cited by 1
Related Papers
Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury
|Proceedings of the National Academy of Sciences|2000|1.4k
Diabetic retinopathy: current understanding, mechanisms, and treatment strategies
|JCI Insight|2017|1k
Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial
|Molecular Medicine|2002|1k
Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress
|Proceedings of the National Academy of Sciences|2001|1k